Trends in mortality, heart transplantation, and left ventricular assist device use in advanced heart failure between 2003 and 2022: data from the Swedish Heart Failure Registry
Open Access
- 1 April 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (4) , 726-737
Abstract
Aims: Advanced heart failure (AdvHF) remains a major clinical challenge, yet contemporary epidemiological real-world data on AdvHF patients are limited. The aim was to assess 20-year trends in clinical characteristics, outcomes, and use of left ventricular assist devices (LVAD) and heart transplantation (HTx) in patients with AdvHF and reduced ejection fraction (AdvHFrEF) in Sweden. Methods and results: Between 2003 and 2022, 5323 patients (median age 76 [IQR 68–82], 23% females) included in the Swedish HF Registry met adapted ESC-HFA criteria for AdvHF (NYHA III–IV, EF <30%, ≥1 HF hospitalization ≤6 months). Of these, 29% were eligible for AdvHF therapies (median age 63 [IQR 57–67] years, 18% females) according to the following additional criteria: ≤70 years old, no dialysis within ≤5 years, no active cancer within ≤3 years. Unadjusted temporal trends in 1-year outcomes (all-cause, CV and non-CV death, HTx, and LVAD implantation) were presented as estimated annual percent change (eAPC). 1-year all-cause mortality declined significantly in the overall cohort (eAPC −3.8; 95%CI −5.3 to −2.2) as well as in patients eligible for AdvHF therapies (eAPC −3.2; 95%CI −6.3 to −0.1) over the study period. These improvements were largely driven by reductions in CV mortality (overall cohort: eAPC −4.3; 95%CI −6.0 to −2.6; eligible cohort: eAPC −5.6, 95%CI −9.4 to −1.7). Use of LVAD significantly increased over the study period, while HTx showed a modest but non-significant rise. Conclusion: In a large nationwide cohort, all-cause and CV-mortality among AdvHFrEF patients markedly declined over the past 20 years, potentially reflecting improvements in treatments. Despite progress, significant opportunities remain to improve access to and adoption of advanced therapies.Keywords
Funding Information
- Hjärt-Lungfonden (20220680)
This publication has 31 references indexed in Scilit:
- Knowledge and Application of ESC/HFA Guidelines in the Management of Advanced Heart FailureEuropean Journal of Heart Failure, 2024
- Trends in Heart Failure Mortality in Sweden Between 1997 and 2022European Journal of Heart Failure, 2024
- Are Mechanical Circulatory Supports the Forgotten Aspect in the Implementation of Therapies for Heart Failure?European Journal of Heart Failure, 2024
- Frailty According to the 2019 HFA-ESC Definition in Patients at Risk for Advanced Heart Failure: Insights from the HELP-HF RegistryEuropean Journal of Heart Failure, 2024
- Guideline-Directed Medical Therapy in Severe Heart Failure with Reduced Ejection Fraction: An Analysis from the HELP-HF RegistryEuropean Journal of Heart Failure, 2023
- Prognostic impact of the updated 2018 HFA‐ESC definition of advanced heart failure: results from the HELP‐HF registryEuropean Journal of Heart Failure, 2022
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 2022
- Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection FractionJAMA Cardiology, 2021
- Randomized Trial of a Left Ventricular Assist Device as Destination Therapy Versus Guideline-Directed Medical Therapy in Patients with Advanced Heart Failure. Rationale and Design of the SWEdish Evaluation of Left Ventricular Assist Device (SweVAD) TrialEuropean Journal of Heart Failure, 2020
- Advanced Heart Failure: A Position Statement of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2018